A Study to Identify Biomarkers of Spinal Muscular Atrophy in Spinraza-Treated Patients

Overview

About this study

The purpose of this study is to identify biomarkers of spinal muscular atrophy in Spinraza-treated patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Inclusion criteria include SMA patients receiving Spinraza. 
  • Males and females of all ages
  • Patients diagnosed with types 1-4.

Exclusion Criteria: 

  • CSF drawn for an indication other than Spinraza injection would be excluded.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Linda Hasadsri, M.D., Ph.D.

Open for enrollment

Contact information:

Sara Cook M.D., Ph.D.

(507)284-1196

Cook.Sara@mayo.edu

La Crosse, Wis.

Mayo Clinic principal investigator

Daniel Anderson, D.O.

Open for enrollment

Contact information:

Lisa Hines

(507)293-1638

Hines.Lisa@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20464384

Mayo Clinic Footer